InvestorsHub Logo
Followers 122
Posts 6384
Boards Moderated 0
Alias Born 08/17/2014

Re: Rogerthat1 post# 16977

Wednesday, 06/29/2016 8:51:32 AM

Wednesday, June 29, 2016 8:51:32 AM

Post# of 34577
It treats a specific Ovarian population. If TPIV targets that same patient population with TPIV200, and the standard of care changes, then each arm will get that new drug; and then TPIV would need to show an improvement upon that, and changes would be made to the protocol to address. As of right now, they are going after the entire Ovarian population that is in remission.This company is not. But TapImmune will address if it changes their game plan at all. It is likely to be synergistic to TPIV's treatment, and the combination could end up extending survival to be cure like.

http://www.publicnow.com/view/83D2FE90506382232956E0CD480AA3A40AD440F2
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRKR News